M.tuberculosis Mutants Lacking Oxygenated Mycolates Show Increased Immunogenicity and Protective Efficacy as Compared to M. bovis BCG Vaccine in an Experimental Mouse Model

• Dorsaf Hedhli,

  Affiliation Service Immunology, Scientific Institute of Public Health (WIV-ISP, Site Ukkel), Brussels, Belgium

  ⨯
• Olivier Denis,

  Affiliation Service Immunology, Scientific Institute of Public Health (WIV-ISP, Site Ukkel), Brussels, Belgium

  ⨯
• Daniel Barkan,

  Current address: Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel

  Affiliation Immunology Program and Division of Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Mamadou Daffé,

  Affiliation Département de Mécanismes Moléculaires des Infections Mycobactériennes, Institut de Pharmacologie et Biologie Structurale du CNRS et de l'Université Paul Sabatier (UMR 5089), Toulouse, France

  ⨯
• Michael S. Glickman,

  Affiliation Immunology Program and Division of Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Kris Huygen

  *E-mail: kris.huygen@wiv-isp.be

  Affiliation Service Immunology, Scientific Institute of Public Health (WIV-ISP, Site Ukkel), Brussels, Belgium

  ⨯